Provided is a novel means for: reducing the risk of cerebral hemorrhage as a result of recanalization therapy for occluded blood vessels (e.g., administration of medical drugs including thrombolytic agent, platelet aggregation inhibitor, and blood coagulation inhibitor, or physical removal of blood clots)； and more effectively treating ischemic vascular disorders. The present invention is a mesenchymal stem cell-containing medical drug for treating ischemic vascular disorders, characterized by being concurrently used with recanalization therapy for occluded blood vessels. More specifically, the present invention is a medical drug for treating ischemic vascular disorders, characterized by reducing the risk of cerebral hemorrhage as a result of recanalization therapy for occluded blood vessels and by extending the period during which the medical drug can be applied.
